Oncology CRO SERVICES

Supporting Patient-Centric Oncology Clinical Trials

PharPoint’s oncology contract research organization (CRO) services help sponsors meet their study goals. 

ONCOLOGY CLINICAL TRIAL OUTSOURCING SUPPORT

Partner with an Attentive Oncology CRO

PharPoint has provided oncology CRO services for Phase 1-4 clinical trials, and works consultatively with sponsors to meet study goals. Our team has experience supporting trials exploring immunotherapies, including cell and gene therapies, along with rare and pediatric oncology indications. PharPoint is also experienced in providing biometrics CRO support according to industry best timelines.

PHARPOINT’S EXPERIENCE INCLUDES:

  • Melanoma
  • Myelofibrosis
  • Leukemia
  • Breast cancer
  • Lymphoma
  • Small cell lung cancer
  • Glioma
  • Non-small cell lung cancer
  • Myleodysplastic syndromes

215+
Oncology trials supported across all services


50+
Oncology indications


AN ONCOLOGY EXPERIENCED CRO

How PharPoint Successfully Supports Oncology Clinical Trials

Align with an experienced team

PharPoint’s team of experts have extensive experience within oncology, including experience with immuno-oncology, solid tumors, and hematologic cancers. This includes an understanding of RECIST criteria and the STING pathway.

PharPoint has experience working with the FDA’s oncology division since 2006, including the successful support of multiple submissions.

Get study results faster

With strategic early planning and collaboration, efficient study processes, and a seasoned study team, PharPoint helps sponsors meet rapid study timelines. For more information about average biometrics CRO timelines, the standard timelines PharPoint provides, and how our team can help you achieve study goals faster, meet with our team.

EXPLORE RELATED RESOURCES

Supporting Blood Cancer Clinical Trials: Predicting Study Challenges

What challenges should teams conducting blood cancer clinical trials anticipate? Learn more about common obstacles and how to overcome them.

Ensuring Consistency in RECIST 1.1 Reads

RECIST criteria is not always reported accurately, and variability in tumor response assessment may be disastrous for measuring true treatment effect. Here's how your CRO can support more consistent RECIST reads.

Immuno-Oncology Clinical Trial Considerations

What do you need to consider when managing/monitoring an immuno-oncology clinical trial? Download PharPoint's fact book to learn more.

ABOUT PHARPOINT

Explore PharPoint’s Oncology CRO Services

PharPoint Research is a client-focused, US-based contract research organization that helps sponsors meet their clinical trial goals.

Our oncology CRO services include:

Confidently make informed decisions and advance your product along the development pathway with support from our regulatory, clinical, medical, and biometrics consultants.

We work to ensure study excellence and transparent collaboration between CRO, site, and Sponsor. Our teams are highly accessible and work closely to build excellent site relationships that streamline communications, encourage efficiency, and ensure compliance.

Receive high quality support and deliverables from our data management and biostatistics teams – all according to our industry-best biometrics timelines.

PharPoint’s medical writing team can provide you with accurate, clear, and concise clinical trial documents.

Concerned your current clinical trial outsourcing partner is placing your study on the backburner? PharPoint’s flexible support includes clinical trial rescue services as well as CRO oversight.

What Our Clients and Partners Say About Working with PharPoint

“My experience working with PharPoint has been a pleasure. They have taken ownership of our clinical trial since day one. I truly feel that we work as one team.”

Sr. Director, Clinical Operations, Biopharmaceutical Client

“PharPoint has been helpful in study rescues, high priority pivotal studies locked and delivered faster than any other CRO I have worked with in my experience.  Not only was the study delivered within budget and early, it was a quality deliverable.”

VP Clinical Operations, Biotechnology client

“In advance I would say that our experience with PharPoint has been very positive. As a smaller company, I was concerned we would get lost and deprioritized with one of the larger CROs, and in fact that had been the case with a prior CRO who we had contracted for our study. We went out to bid for a new CRO and the PharPoint team came out of nowhere with an excellent pitch. Not knowing them as well as larger competitors we were cautious, but they delivered thoughtful responses and solutions at every stage. We decided to move forward with them and I can honestly say I have never had any feelings of buyer’s remorse or any observed any bait and switch – they remained as committed to our mission over the period we worked with them as they were in the initial meetings.”

US General Manager, Pharmaceutical client

“I can highly recommend partnering with PharPoint.  Not only were documents provided to our site in a timely manner, communication with all parties from the CRA to the project managers has been excellent.  Our site has not had any trouble with reaching our PharPoint contacts when in need of assistance, either by email or phone. When follow up is required, I can count on it being addressed quickly and accurately.”

Site coordinator, study partner

Reach Out to an Experienced Oncology CRO Team